Pd-169316

Pd-169316

SCHEMBL9899161

O=[N+]([O-])c1ccc(-c2nc(-c3ccncc3)c(-c3ccc(F)cc3)[nH]2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 1.00
MAPK11 Q15759 16/20 1.00
MAPK13 O15264 15/20 1.00
MAPK12 P53778 15/20 1.00
ALOX5 P09917 12/20 1.00
ALDH1A1 P00352 4/20 1.00
RIPK2 O43353 3/20 1.00
CYP3A4 P08684 3/20 1.00
ALOX15 P16050 3/20 1.00
MAPK1 P28482 3/20 1.00
GMNN O75496 2/20 1.00
LMNA P02545 2/20 1.00
MAPT P10636 2/20 1.00
NFKB1 P19838 2/20 1.00
THPO P40225 2/20 1.00
BLM P54132 2/20 1.00
PMP22 Q01453 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pd-169316 SCHEMBL154958 1.00 MAPK14 (1.00) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL13741880 0.89 MAPK11 (0.80) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL6449323 0.87 MAPK14 (0.77) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL2125126 0.87 MAPT (0.75) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL19868925 0.87 MAPK11 (1.00) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL15075603 0.87 MAPK11 (1.00) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL31029949 0.82 MAPK14 (0.70) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL17002220 0.82 MAPK14 (0.69) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL6469468 0.82 MAPK11 (0.69) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL4552316 0.81 MAPK14 (1.00) MAPK14MAPK11MAPK13MAPK12ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180071376-A1 TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2018-03-15 US claimed
EP-3274053-A1 TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS The Brigham and Women's Hospital, Inc. (US) 2018-01-31 EP claimed
WO-2016154362-A1 TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2016-09-29 WO claimed
EP-4324913-A2 CULTURE MEDIA FOR STEM CELLS Koninklijke Nederlandse Akademie van Wetenschappen (KNAW) (NL) 2024-02-21 EP disclosed
US-20230357714-A1 STEM CELL CULTURE SYSTEMS FOR COLUMNAR EPITHELIAL STEM CELLS, AND USES RELATED THERETO UNIVERSITY OF HOUSTON SYSTEM (US) 2023-11-09 US disclosed
EP-3318627-B1 CULTURE MEDIA FOR STEM CELLS KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN KNAW (NL) 2023-10-25 EP disclosed
US-10441577-B2 Medicament for treatment of liver cancer HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (DE) 2019-10-15 US disclosed
EP-3318627-A1 CULTURE MEDIA FOR STEM CELLS Koninklijke Nederlandse Akademie van Wetenschappen (KNAW) (NL) 2018-05-09 EP disclosed
US-20180071376-A1 TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2018-03-15 US disclosed
EP-3274053-A1 TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS The Brigham and Women's Hospital, Inc. (US) 2018-01-31 EP disclosed
EP-2718422-B1 CULTURE MEDIA FOR STEM CELLS KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (KNAW) (NL) 2017-09-06 EP disclosed
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED (GB) 2016-12-08 US disclosed
WO-2016154362-A1 TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2016-09-29 WO disclosed
US-20150079154-A1 MEDICAMENT FOR TREATMENT OF LIVER CANCER HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) 2015-03-19 US disclosed
US-20140163028-A1 INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER (US) 2014-06-12 US disclosed
US-20140031547-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES ELECTROPHORETICS LIMITED 2014-01-30 US disclosed
US-20120151612-A1 NON-SURGICAL APPROACH TO PREVENT AND CORRECT CRANIOFACIAL MALFORMATIONS DURING DEVELOPMENT UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2012-06-14 US disclosed
US-20110212475-A1 Fluorescently Or Spin-Labeled Kinases For Rapid Screening And Identification Of Novel Kinase Inhibitor Scaffolds MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031547-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1G3 MAPK14 871/4885MAPK11 1082/4885MAPK13 884/4885
US-20160354375-A1 CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES CSNK1G1, CSNK1A1, CSNK1D MAPK14 636/4885MAPK11 865/4885MAPK13 715/4885
US-20120151612-A1 NON-SURGICAL APPROACH TO PREVENT AND CORRECT CRANIOFACIAL MALFORMATIONS DURING DEVELOPMENT TGFBR2, TGFBR1, BMPR2 MAPK14 55/4885MAPK11 65/4885MAPK13 62/4885
US-20180071376-A1 TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS IAPP, NFATC1, CD4 MAPK14 2820/4885MAPK11 2451/4885MAPK13 1694/4885
US-20140163028-A1 INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 TNK2, CDC42BPA, CDC42BPG MAPK14 168/4885MAPK11 469/4885MAPK13 274/4885
US-10441577-B2 Medicament for treatment of liver cancer PYGL, PFKL, GLS2 MAPK14 523/4885MAPK11 684/4885MAPK13 685/4885
US-20150079154-A1 MEDICAMENT FOR TREATMENT OF LIVER CANCER PYGL, PFKL, GLS2 MAPK14 523/4885MAPK11 684/4885MAPK13 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.